Jubilant Pharmova Ltd (Jubilant) manufactures and supplies active pharmaceutical ingredients (APIs), solid dosage formulations, allergy therapy products and radiopharmaceuticals. Jubilant offers contract manufacturing services for sterile injectables and non-sterile products and drug discovery services.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Jubilant is committed to advancing innovation, scientific efficiency, and effectiveness through its R&D efforts, aligning with its core values and strategic business objectives. The R&D centers, based in North America, specialize in developing robust, non-infringing processes for niche formulations and radiopharmaceuticals. Jubilant’s multi-disciplinary R&D teams, skilled across the pharmaceutical value chain, focus on various domains including novel drug delivery systems, radiopharmaceuticals, allergenic extracts, and analytical research. The company’s R&D endeavours in radiopharmaceuticals are led by a specialised team based in Montreal, Canada, with additional support teams in India and the US. This team focuses on nuclear medicine for diagnosing, treating, and monitoring diseases, including cancer, through radiopharmaceutical agents. The team serves global hospital-based customers and radiopharmacies with high-quality speciality products. Recent achievements include the successful launch of Mertiatide and Sulfur Colloid and the FDA-approved Ruby-Fill Cardiac imaging in mobile vans. The company is also advancing therapeutic products like I31MIBG, currently in clinical trials. In the field of allergenic extracts, Jubilant’s R&D focuses on biopharmaceuticals and sterile liquid vaccines, particularly allergen extracts for immunotherapy. The company’s cGMP facility adheres to high industry standards, serving allergists, ENT specialists, and other healthcare providers across the US, Canada, Australia, and other international markets. In the Generics Business, the company has filed 101 ANDAs in the US, 39 in Europe, 29 in the UK, 25 in Canada, and 45 in other countries. It has received 63 approvals in the US, 23 in the UK, 37 in Europe, 24 in Canada, and 42 in other markets. Jubilant’s goal is to launch 6 to 8 products annually in the UK and UAE, as well as 6 to 8 products in the US market through in-licensing and contract manufacturing. The company’s Drug Discovery Services offer cutting-edge capabilities in small molecule discovery and pre-clinical development, including Discovery Informatics, Molecular Modelling, Structural Biology, Medicinal Chemistry, Synthetic Chemistry, in-vitro and in-vivo Biology, DMPK studies, Pharmacology, Toxicology, Scale-up, and GMP. The company's therapeutic focus includes oncology, metabolic disorders, neurological disorders, and inflammation. Recent additions to the company’s technology suite include the mosquito Xtal3 liquid handling system, mass spectrometers, and the IVIS Spectrum in vivo imaging system, enhancing its capabilities in protein crystallization and non-invasive monitoring of disease progression. In FY2025, the company’s R&D expenditure stood at INR127 million, which declined 42% YoY and accounted for 0.2% of the company’s total revenue.